Peter Dudek

Peter Dudek has a diverse work experience, primarily in the biotechnology and pharmaceutical industry. Peter is currently serving as a Board Director at InduPro since February 2022. Before that, they were a Board Observer at Photys Therapeutics starting from December 2021 and a Board Director at Caraway Therapeutics, Inc. and Tallac Therapeutics from November 2021. Prior to these roles, they were associated with Merck, where they held various positions. Peter served as the President & Managing Partner of MRL Ventures Fund since March 2021 and as a Partner of MRL Ventures Fund from April 2018 until March 2021. Other notable roles include serving as a Board Director at Mozart Therapeutics, Inc. from December 2020 and as a Board Director at Ambagon Therapeutics from July 2020. Peter has also been a Board Observer at Carisma Therapeutics since June 2018, which will continue until March 2023. Furthermore, they served as a Board Observer at LifeMine Therapeutics from November 2021 until January 2023 and at HotSpot Therapeutics, Inc. from April 2020 until September 2022. Peter Dudek's work experience showcases their extensive involvement in the biotech industry, holding various leadership positions and providing expertise as a board member and observer in multiple organizations.

Peter Dudek's education history is as follows:

- In 2009, they attended the University of Oxford for the Technology Spin-out Management Programme.

- From 2007 to 2009, they studied at Saïd Business School, University of Oxford, focusing on Building a Business and Medical Innovation.

- Peter obtained their Doctor of Philosophy degree in Cell Biology from the University of Geneva between 2000 and 2006.

- Prior to that, from 1998 to 2000, they completed their Bachelor of Science (Hons) in Molecular Microbiology and Immunology at The University of British Columbia.

- Between 1996 and 1998, they attended Capilano University, where they earned an Associate of Science degree in Science.

- Finally, from 1992 to 1996, they attended WDHS, though no degree or field of study information was provided for this period.